Claims
- 1. A process for inhibiting tumorous growth comprising the step of treating said tumorous growth, in vivo, with an endogenous endorphin.
- 2. A process of claim 1 wherein said endogenous endorphin is selected from the group consisting of beta-endorphin [61-91] and peptides of which beta-endorphin [61-91] is the precursor.
- 3. A process of claim 1 wherein said endogenous endorphin is selected from the group consisting of methionine-enkephalin, leucine-enkephalin, [arg.sup.6 ]-leucine-enkephalin, alpha-neo-endorphin, beta-neo-endorphin, dynorphin, PH-8P (dynorphin [1-8]), and beta-endorphin.
- 4. A process of claim 1 wherein said endogenous endorphin is leucine-enkephalin.
- 5. A process of claim 1 wherein said endogenous endorphin is methionine-enkephalin.
- 6. A process of claim 4 wherein said enkephalin is administered in the range from about 0.001 to about 30 mg/kg.
- 7. A process of claim 5 wherein said enkephalin is administered in the range from about 0.001 to about 30 mg/kg.
- 8. A process for stimulating the natural immune system resisting tumorous growth comprising the step of treating the tumorous growth, in vivo, with an endogenous endorphin.
- 9. A process of claim 8 wherein said endogenous endorphin is selected from the group consisting of beta-endorphin [61-91] and peptides of which beta-endorphin [61-91] is the precursor.
- 10. A process of claim 8 wherein said endogenous endorphin is selected from the group consisting of methionine-enkephalin, leucine-enkephalin, [arg.sup.6 ]-leucine-enkephalin, alpha-neo-endorphin, beta-neo-endorphin, dynorphin, PH-8P (dynorphin [1-8]), and beta-endorphin.
- 11. A process of claim 8 wherein said endogenous endorphin is leucine-enkephalin.
- 12. A process of claim 8 wherein said endogenous endorphin is methionine-enkephalin.
- 13. A process of claim 11 wherein said enkephalin is administered in the range from about 0.001 to about 30 mg/kg.
- 14. A process of claim 12 wherein said enkephalin is administered in the range from about 0.001 to about 30 mg/kg.
- 15. A process for the therapeutic treatment of cancer comprising the step of administering an effective dosage of an endogenous endorphin.
- 16. A process of claim 15 wherein said endogenous endorphin is selected from the group consisting of the following table:
- Met-enkephalin
- Leu-enkephalin
- (Arg.sup.6)-Leu-enkephalin
- (Arg.sup.6)-Met-enkephalin
- (Lys.sup.6)-Met-enkephalin
- (Arg.sup.6 -Arg.sup.7)-Met-enkephalin
- (Arg.sup.6 -Phe.sup.7)-Met-enkephalin
- (Arg.sup.6 -Gly.sup.7 -Leu.sup.8)-Met-enkephalin
- Alpha-Neo-endorphin
- Beta-Neo-endorphin
- Dynorphin
- Ph-8P(Dunorphin(1-8)).
- 17. A process of claim 15 wherein said endogenous endorphin is leucine-enkephalin.
- 18. A process of claim 15 wherein said endogenous endorphin is methionine-enkephalin.
- 19. A process of claim 17 wherein said enkephalin is administered in the range from about 0.001 to about 30 mg/kg.
- 20. A process of claim 18 wherein said enkephalin is administered in the range from about 0.001 to about 30 mg/kg.
- 21. A process of claim 15 wherein endogenous endorphin is administered in a dosage range from about 0.25 mg/kg to about 10.sup.-14 mg/kg.
- 22. A process of claim 16 wherein endogenous endorphin is administered in a dosage range from about 0.25 mg/kg to about 10.sup.-14 mg/kg.
- 23. A process of claim 17 wherein endogenous endorphin is administered in a dosage range from about 0.25 mg/kg to about 10.sup.-14 mg/kg.
- 24. A process of claim 18 wherein said leucine-enkephalin is administered in a dosage range from about 0.25 mg/kg to about 10.sup.-14 mg/kg.
CROSS-REFERENCE TO RELATED APPLICATIONS
This is a continuation of co-pending application Ser. No. 928,721, filed on 11/7/86, which is a continuation of copending application Ser. No. 698,037 filed on Feb. 4, 1985, which is a continuation-in-part of Ser. No. 597,378 filed on Apr. 6, 1984, now U.S. Pat. No. 4,537,878, which is a continuation-in-part of Ser. No. 308,287 filed on Oct. 5, 1981, now abandoned.
US Referenced Citations (1)
Number |
Name |
Date |
Kind |
4537878 |
Plotnikoff |
Aug 1985 |
|
Non-Patent Literature Citations (3)
Entry |
Chem. Absts. vol. 96, (1982) 29203m. |
Chem. Abstr. vol. 100, (1984) 173021u. |
Internat'l Symposium on New Trends in human Immun & Cancer Immunotherapy (1980)48-55. |
Continuations (2)
|
Number |
Date |
Country |
Parent |
928721 |
Nov 1986 |
|
Parent |
698037 |
Feb 1985 |
|
Continuation in Parts (2)
|
Number |
Date |
Country |
Parent |
597378 |
Apr 1984 |
|
Parent |
308287 |
Oct 1981 |
|